A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
Solid Tumors
DRUG: CYC116
Safety and tolerability, Safety and tolerability; SAEs and AEs, over the course of study
Phase I study of an investigational cancer drug, CYC116, an Aurora kinase inhibitor, in patients with advanced solid tumors.